Daniel Kirby
Overview
Explore the profile of Daniel Kirby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabra R, Kirby D, Chouk V, Malgorzata K, Mohammed A
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771541
Buccal drug delivery emerges as a promising strategy to enhance the absorption of drugs classified under the Biopharmaceutics Classification System (BCS) Class III, characterized by high solubility and low permeability....
2.
Khan D, Kirby D, Bryson S, Shah M, Mohammed A
Int J Pharm
. 2022 Jan;
616:121501.
PMID: 35092832
The total number of paediatric formulations available only account for a small proportion of the full therapeutic plethora required to effectively treat paediatrics and, therefore, the availability of high quality...
3.
Khan D, Kirby D, Bryson S, Shah M, Mohammed A
Pharmaceutics
. 2021 Jul;
13(6).
PMID: 34204941
Owing to considerable differences observed in anatomy and physiology between paediatric subsets, it has been well established that children respond to drugs differently compared to adults. Furthermore, from a formulation...
4.
George M, Baker J, Banerjee S, Busch H, Curtis D, Danila M, et al.
ACR Open Rheumatol
. 2021 May;
3(6):381-389.
PMID: 33934576
Background: We aimed to compare concerns, social distancing, health care disruptions, and telemedicine use in patients with autoimmune rheumatic disease (ARD) and non-ARD and to evaluate factors associated with immunomodulatory...
5.
Ershad A, Rajabi-Siahboomi A, Missaghi S, Kirby D, Mohammed A
Pharmaceutics
. 2021 Apr;
13(3).
PMID: 33808875
A lack of effective intervention in addressing patient non-adherence and the acceptability of solid oral dosage forms combined with the clinical consequences of swallowing problems in an ageing world population...
6.
Shariff Z, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I
Pharmaceutics
. 2020 Sep;
12(10).
PMID: 32977445
Older people represent a very heterogeneous patient population and are the major user group of medication. Age-related changes mean that this population can encounter barriers towards taking medicines orally. The...
7.
Koner J, Rajabi-Siahboomi A, Missaghi S, Kirby D, Perrie Y, Ahmed J, et al.
Sci Rep
. 2019 Aug;
9(1):12467.
PMID: 31462654
Disintegration time is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT). The currently accepted in vitro testing regimen for ODTs is the standard ...
8.
Joshi S, Bawage S, Tiwari P, Kirby D, Perrie Y, Dennis V, et al.
Expert Opin Drug Deliv
. 2019 Aug;
16(9):969-980.
PMID: 31382795
: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis...
9.
Loebermann M, Fritzsche C, Geerdes-Fenge H, Heijnen E, Kirby D, Reisinger E
Infection
. 2018 Oct;
47(1):105-109.
PMID: 30298473
Vaccination is an essential tool in reducing the impact of seasonal influenza infections. The viral strains responsible for seasonal outbreaks vary annually, and preventive vaccines have to be adapted accordingly....
10.
Koner J, Rajabi-Siahboomi A, Bowen J, Perrie Y, Kirby D, Mohammed A
Sci Rep
. 2015 Nov;
5:16352.
PMID: 26553127
Mannitol is an essential excipient employed in orally disintegrating tablets due to its high palatability. However its fundamental disadvantage is its fragmentation during direct compression, producing mechanically weak tablets. The...